

CANCER DE L'OVAIRE

Année 2021

DESKTOP III

Philipp Harter 1, Jalid Sehouli 1, Ignace Vergote 1, Gwenaël Ferron 1, Alexander Reuss 1, Werner Meier 1, Stefano Greggi 1, Berit J Mosgard 1, Frederic Selle 1, Frédéric Guyon 1, Christophe Pomel 1, Fabrice Lécuru 1, Rongyu Zang 1, Elisabeth Avall-Lundqvist 1, Jae-Weon Kim 1, Jordi Ponce 1, Francesco Raspagliesi 1, Gunnar Kristensen 1, Jean-Marc Classe 1, Peter Hillemanns 1, Pernille Jensen 1, Annette Hasenburger 1, Sadaf Ghaem-Maghani 1, Mansoor R Mirza 1, Bente Lund 1, Alexander Reinhaller 1, Ana Santaballa 1, Adeola Olaitan 1, Felix Hilpert 1, Andreas du Bois 1, DESKTOP III Investigators

[Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer](#)

N Engl J Med 2021 Dec 2;385(23):2123-2131

EWOC-1

Claire Falandry et al

[Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial](#)

JAMA Oncol 2021 Jun 1;7(6):853-861

ENCOURAGE

Dominique Berton & al

[Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients](#)

Front Pharmacol 2021 Sep 20;12:711813

REGOVAR

Olivier Trédan & al

[Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial \(REGOVAR\)](#)

Gynecol Oncol 2021 Oct 22;S0090-8258(21)01402-5

VIVROVAIRE

PUBLICATION DU GINECO

François Gernier & al

Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors

BMC Cancer 2021 Oct 26;21(1):1147

PAOLA-1 vs SOLO1

Ignace Vergote 1, Isabelle Ray-Coquard 2, Daniel M Anderson 3, Guilherme Cantuaria 4, Nicoletta Colombo 5, Claire Garnier-Tixidre 6, Lucy Gilbert 7, Philipp Harter 8, Robert Hettle 9, Domenica Lorusso 10, Johanna Mäenpää 11, Christian Marth 12, Koji Matsumoto 13, Mario Ouwens 9, Andrés Poveda 14, Francesco Raspagliesi 15, Kirsty Rhodes 9, María J Rubio Pérez 16, Ronnie Shapira-Frommer 17, Ayumi Shikama 18, Magdalena Sikorska 19, Kathleen Moore 20, Paul DiSilvestro

Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer

Eur J Cancer 2021 Sep 27;157:415-423

PAOLA-1 – Subset Japan

Keiichi Fujiwara ,1 Hiroyuki Fujiwara ,2 Hiroyuki Yoshida ,1 Toyomi Satoh ,3 Kan Yonemori ,4 Shoji Nagao ,5 Takashi Matsumoto ,6 Hiroaki Kobayashi ,7 Hughes Bourgeois ,8 Philipp Harter ,9 Anna Maria Mosconi ,10 Isabel Palacio Vazquez ,11 Alexander Reinthaller ,12 Tomoko Fujita ,13 Philip Rowe ,14 Eric Pujade-Lauraine ,15 Isabelle Ray-Coquard

Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial

J Gynecol Oncol. 2021 Sep;32(5):e82

JAVELIN 200

Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ.

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

Lancet Oncol. 2021 Jul;22(7):1034-1046

MITO16

PUBLICATION DU GINECO

Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Cristiana Sessa, Aristotelis Bamias, Vanda Salutari, Frédéric Selle, Simona Frezzini, Ugo De Giorgi, Patricia Pautier, Alessandra Bologna, Michele Orditura, Coraline Dubot, Angiolo Gadducci, Serafina Mammoliti, Isabelle Ray-Coquard, Elena Zafarana, Enrico Breda, Laure Favier, Antonio Ardizzoia, Saverio Cinieri, Rémy Largillier, Daniela Sambataro, Emmanuel Guardiola, Rossella Lauria, Carmela Pisano, Francesco Raspagliesi, Giovanni Scambia, Gennaro Daniele, Francesco Perrone, on behalf of the MITO16b/MANGO–OV2/ENGOT–ov17 Investigators*

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Lancet Oncol , volume 22, Feb 21

CHIVA – TEP scan

Aide N, Fauchille P, Coquan E, Ferron G, Combe P, Meunier J, Alexandre J, Berton D, Leary A, De Rauglaudre G, Bonichon N, Pujade Lauraine E, Joly F

Predicting tumor response and outcome of second-look surgery with 18 F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer

Eur J Nucl Med Mol Imaging 2021 Jun;48(6):1998-2008

SOLO2 – Nomogramme

Tjokrowidjaja A, Friedlander M, Lord SJ, Asher R, Rodrigues M, Ledermann JA, Matulonis UA, Oza AM, Bruchim I, Huzarski T, Gourley C, Harter P, Vergote I, Scott CL, Meier W, Shapira-Frommer R, Milenkova T, Pujade-Lauraine E, GebSKI V, Lee CK

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

Eur J Cancer. 2021 Sep;154:190-200

SOLO2 OS

*Andrés Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjong-Won Park-Simon, Kenji Tamura, Gabe S Sonke, Alla Lisyanskaya, Jae-Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S Lowe, Phil Rowe, Ignace Vergote, Eric Pujade-Lauraine, the SOLO2/ENGOT-Ov21 investigators**

PUBLICATION DU GINECO

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a *BRCA1/2* mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Lancet Oncol , March 21

Autres Publications du Groupe

Année 2021

GCIg méta-analyse

Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, Scott CL; Gynecologic Cancer Intergroup Meta-Analysis Committee.

Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis

Cancer. 2021 Jul 15;127(14):2432-2441

GCIg Symptom benefit

Jean-Emmanuel Kurtz 1, Val GebSKI 2, Vladyslav Sukhin 3, Mark Carey 4, Iwa Kong 5, Rosalind M Glasspool 6, Jonathan S Berek 7, Mariana de Paiva Batista 8, Marcia Hall 9, Jae-Weon Kim 10, Effi Yeoshoua 11, Noriko Fujiwara 12, Byung-Ho Nam 13, Sandra Polleis 14, Jung-Yun Lee 15, Aleksandra Strojna 16, Laura Farrelly 17, Richard Schwameis 18, Roldano Fossati 19, Anne-Sophie Darlington 20, Chyong-Huey Lai 21, Alexi A Wright 22, Orgad Rosenblat 23, Phillip Harter 24, Patricia Roxburgh 25, Rahul Roy Chowdhury 26, Ting-Chang Chang 27, Xavier Paoletti 28, Michael Friedlander

Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIg symptom benefit committee

Gynecol Oncol 2021 May;161(2):502-507